Health Care · Pharmaceutical Preparations

ALNY Alnylam Pharmaceuticals SEC Filings & Insider Trading Activity 2026

company
CIK 1178670107 filings
Nasdaq 100

ALNY at a glance

Alnylam Pharmaceuticals (ALNY, SEC CIK 1178670) filed its latest 10-K annual report on February 12, 2026, a 10-Q quarterly report on October 29, 2026, an 8-K current report on November 5, 2026 and Form 4 insider filings as recently as November 17, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.

  • For the fiscal year ended December 31, 2025 (FY2025), Alnylam Pharmaceuticals (ALNY) reported revenue of $3.7 billion (up 65.2% from FY2024) and net income of $313.7 million. Diluted EPS was $2.33.
  • As of September 30, 2026, 38 institutional investment managers tracked by SignalX reported holding Alnylam Pharmaceuticals (ALNY) shares worth $10.9 billion in 13F-HR filings.
  • The most recent insider open-market purchase reported on Form 4 was by Sigal Charles Elliott on November 10, 2026 of 1,600 shares at $152.25 per share.
  • In the last 90 days, ALNY insiders reported 2 open-market purchases ($543K) and 1 open-market sale ($399K) on Form 4, a net purchase of $144K.

Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).

Revenue · FY2025
$3.7B
+65.2% vs prior year
Insiders · 90 days
2 buys · 1 sell
Net +$144K
13F holders
38 funds
$10.9B · −1 vs prior quarter
Latest 8-K
Nov 5, 2026
Item 5.02 · Item 8.01

AI 10-K Annual Report Analysis

Latest 10-K, fiscal year ended Dec 31, 2025

Full analysis →

Business Overview

  • Achieved first profitability in 2025 with net product revenues approx. $3.0B, primarily from TTR franchise growth
  • Initiated Phase 3 trials in 2025 for nucresiran (next-gen TTR silencer) and zilebesiran (hypertension), emphasizing late-stage pipeline expansion
  • Strategic focus on Alnylam 2030: 10 tissue types, 40+ clinical programs, 30% revenues in R&D, 25%+ CAGR, targeting two blockbusters beyond TTR
  • Net product revenues up 81% YoY to $2.99B driven by AMVUTTRA growth (+138% to $2.31B), offset by ONPATTRO decline (-32% to $173M)
  • Paid $1.15B to repurchase convertible notes in 2025; raised $645.7M from 0.00% Convertible Senior Notes due 2028 issuance

Risk Factors

  • Regulatory risk from U.S. drug price control measures, Medicare/Medicaid reimbursement changes potentially reducing AMVUTTRA net price
  • Geopolitical exposure to foreign currency fluctuations in Japanese yen, Euro, and British pound affecting revenues and expenses
  • Operational reliance on third-party manufacturing and clinical trial partners to supply and develop AMVUTTRA and other products
  • Market disruption risk from generic competition and emerging therapies targeting ATTR-CM and hATTR-PN indications
  • Financial risk tied to royalty sale of Leqvio with $1.00B sales threshold by 12/31/2029 impacting future royalty retention percentages

AI summary of the ALNY 10-K filed . Generated from the filing text; verify against the original.View on SEC EDGARHow to read a 10-K

AI 10-Q Quarterly Report Analysis

Latest 10-Q, quarter ended Sep 30, 2026

Risk Factors

  • New regulatory risk: October 2025 subpoena on government price reporting for four products, with U.S. Attorney engagement continuing
  • New legal risk: Cipla’s September 2026 lawsuit challenging AMVUTTRA patents through an FDA generic application
  • Operational risk: AMVUTTRA generic competition could affect product sales following Cipla’s abbreviated new drug application
  • Financial risk: $362.8 million of 2027 convertible notes classified current, maturing September 15, 2027
  • Collaboration risk: Regeneron’s Initial Research Term expired in May 2026, ending exclusivity for new eye and CNS discovery programs

Management Discussion & Analysis

  • Q3 revenue $1.458B, up from $1.249B YoY, a $209.1M increase
  • Operating margin 23.7% vs 29.5% YoY, net income $2.167B vs $292.7M
  • Best performer AMVUTTRA: $1.130B revenue vs $685.3M, up $445.1M
  • Worst performer ONPATTRO: $19.6M revenue vs $39.1M, down $19.5M
  • Nine-month operating cash flow $738.2M vs $306.4M, with $700.7M used in investing activities

AI summary of the ALNY 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K

AI 8-K Current Report Analysis

The most recent material events, by 8-K item

Filed Nov 5, 2026Full analysis →

Item 5.02: Departure/Appointment of Directors or Principal Officers

  • Chief Commercialization Officer Tolga Tanguler departing in December 2026
  • Planned written separation agreement, terms not yet disclosed

Item 8.01: Other Events

  • $1.0 billion share repurchase authorization, signaling capital return and potential support for ALNY’s stock
  • Approximately $500 million targeted for repurchase by end-2026, with the balance planned during 2027
Filed Oct 29, 2026Full analysis →

Item EX-99.1: Item EX-99.1

  • Q3 revenue $1.46B, up 17%, led by net product revenue $1.29B, up 52%, reinforcing commercial momentum
  • AMVUTTRA revenue $1.13B, up 65%, while ONPATTRO fell 50% to $20M, signaling portfolio migration toward newer therapy

Item 2.02: Results of Operations and Financial Condition

  • Q3 2026 financial results announced for quarter ended September 30, 2026
  • Full earnings release in Exhibit 99.1, the key source for revenue, profitability and guidance details
Filed Jul 30, 2026Full analysis →

Item 2.02: Results of Operations and Financial Condition

  • Alnylam announced financial results for the quarter ended June 30, 2026
  • Detailed operating results and management commentary contained in Exhibit 99.1

Item EX-99.1: Item EX-99.1

  • Q2 revenue $1.291B, up 67%, with GAAP net income $164.5M versus a $72.2M loss
  • AMVUTTRA revenue $1.012B, up 106%, driving total TTR revenue $1.030B, up 89%

AI summaries of ALNY 8-K current reports filed with the SEC. What 8-K item codes mean

SignalX for ALNY

Don't miss the next ALNY filing

  • Alerts as it files. A push when ALNY files an 8-K or an insider trades.
  • Fund moves. Which tracked funds opened, added or cut ALNY, by share count.
  • Ask anything. An AI agent that reads every ALNY filing and answers with sources.

ALNY alerts on your phone. Follow it in the SignalX Android app.

Get it on Google Play

Recent Insider Transactions (Form 4)

Latest reported trades by officers, directors and 10% owners

InsiderTypeDatePrice
Greenstreet YvonneGNov 13, 2026-
PYOTT DAVID E IMNov 10, 2026$71.99
PYOTT DAVID E IMNov 10, 2026-
Sigal Charles ElliottBuyNov 10, 2026$152.25
SCHULMAN AMY WBuyNov 9, 2026$156.82
SUPRAN BRYANSellOct 2, 2026$226.88
Greenstreet YvonneASep 19, 2026-
SCHULMAN AMY WMMay 13, 2026-

Financial Summary
XBRL

Annual financial summary from SEC XBRL data
MetricFY2023FY2024FY2025
Profitability
Revenue-$2.2B$3.7B
Operating Income--$176.9M$501.6M
Net Income-$440.2M-$278.2M$313.7M
Op. Margin--7.9%13.5%
Net Margin--12.4%8.4%
Balance Sheet
Total Assets$3.8B$4.2B$5.0B
Equity-$67.1M$789.2M
ROE--414.6%39.8%
Per Share
EPS$-3.52$-2.18$2.33
Cash Flow
Operating CF--$8.3M$524.1M
CapEx$62.2M$34.3M$58.7M

Source: XBRL data in Alnylam Pharmaceuticals (ALNY)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →

13F Fund Holdings: Quarterly Trend

Latest: Q3 2026

Aggregate ALNY share value held by 13F filers tracked by SignalX, by quarter.

Quarterly totals table
ALNY shares held by 13F filers tracked by SignalX, by quarter
QuarterFundsTotal value
Q3 202638$10.93B
Q2 202639$18.03B
Q1 202638$20.78B
Q4 202536$24.88B
Q3 202539$30.03B
Q2 202534$19.81B
Q1 202533$12.52B
Q4 202429$9.27B
Position changes: Q2 2026 → Q3 2026
Top Buyers
Top Sellers
Closed Positions

Source: 13F-HR filings on SEC EDGAR (aggregated from 286 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work

ALNY filing archive

AI analysis pages for each 10-K, 10-Q and 8-K

Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4

FormFiling dateAnalysisSEC
4Nov 17, 2026--
4Nov 12, 2026--
4Nov 12, 2026--
4Nov 12, 2026--
8-KNov 5, 2026Analysis-
8-KOct 29, 2026Analysis-
10-QOct 29, 2026Analysis
4Oct 6, 2026--
4Sep 22, 2026--
8-KJul 30, 2026Analysis-
10-QJul 30, 2026Analysis
8-KMay 27, 2026Analysis
4May 14, 2026-
8-KApr 30, 2026Analysis-
10-QApr 30, 2026Analysis
SC 13GApr 29, 2026-
4Apr 7, 2026--
4Mar 6, 2026--
4Mar 6, 2026--
4Mar 6, 2026--
4Mar 6, 2026--
4Mar 6, 2026--
8-KMar 4, 2026Analysis-
4Mar 4, 2026--
4Mar 4, 2026--

Related Health Care companies

All Health Care →

ALNY SEC filings: frequently asked questions

Are ALNY insiders buying or selling?

In the last 90 days, Alnylam Pharmaceuticals (ALNY) officers, directors and 10% owners reported 2 open-market purchases worth $543,126 by 2 insiders and 1 open-market sale worth $398,855 by 1 insider on Form 4, a net purchase of $144,271. Many insider sales are pre-planned or for taxes, so purchases usually carry more information.

Which institutions hold ALNY stock?

As of September 30, 2026, the largest Alnylam Pharmaceuticals (ALNY) holders among the 13F filers tracked by SignalX were BlackRock ($2.7 billion), Vanguard Portfolio Management LLC ($1.7 billion), Vanguard Capital Management LLC ($1.5 billion), State Street Corp ($941.9 million), Invesco Ltd ($922.3 million). 13F-HR reports are filed up to 45 days after each quarter ends.

What was ALNY's revenue in fiscal year 2025?

For the fiscal year ended December 31, 2025 (FY2025), Alnylam Pharmaceuticals (ALNY) reported revenue of $3.7 billion (up 65.2% from FY2024) and net income of $313.7 million. Diluted EPS was $2.33. The figures come from the XBRL data in the 10-K.

What are the main risks in ALNY's latest 10-K?

In the 10-K filed February 12, 2026, Alnylam Pharmaceuticals (ALNY) flagged: Regulatory risk from U.S. drug price control measures, Medicare/Medicaid reimbursement changes potentially reducing AMVUTTRA net price. Geopolitical exposure to foreign currency fluctuations in Japanese yen, Euro, and British pound affecting revenues and expenses. (AI summary of the Risk Factors section.)

What did ALNY report in its latest 8-K?

Alnylam Pharmaceuticals (ALNY) filed an 8-K on November 5, 2026 reporting Item 5.02 (Departure/Appointment of Directors or Principal Officers) and Item 8.01 (Other Events). Chief Commercialization Officer Tolga Tanguler departing in December 2026.

What are the latest ALNY SEC filings?

Alnylam Pharmaceuticals (ALNY) filed its latest 10-K annual report on February 12, 2026, a 10-Q quarterly report on October 29, 2026, an 8-K current report on November 5, 2026 and a Form 4 insider filing on November 17, 2026.

What is ALNY's SEC CIK number?

Alnylam Pharmaceuticals (ALNY)'s SEC Central Index Key (CIK) is 1178670. EDGAR lists every ALNY filing under that number.

Ask anything about ALNY

The research agent reads ALNY's filings, financials, insider trades and 13F holders, then answers with sources.